A gas chromatography/electron capture/negative chemical ionization high-resolution mass spectrometry method for analysis of endogenous and exogenous N7-(2-hydroxyethyl)guanine in rodents and its potential for human biological monitoring.

A gas chromatography/electron capture/negative chemical ionization high-resolution mass spectrometry (GC/EC/NCI-HRMS) method was developed for quantitating N7-(2-hydroxyethyl)guanine (N7-HEG) with excellent sensitivity and specificity. [4,5,6,8-(13)C(4)]-N7-HEG was synthesized, characterized, and quantitated using HPLC/electrospray ionization mass spectrometry (HPLC/ESI-MS) so it could serve as an internal standard. After being converted to its corresponding xanthine and derivatized with pentafluorobenzyl (PFB) bromide twice, the PFB derivative of N7-HEG was characterized using GC/EC/NCI-HRMS carried out at full scan mode. The most abundant fragment was at m/z 555, with a molecular formula of C(21)H(9)N(4)O(3)F(10), resulting from the loss of one PFB group. By monitoring m/z 555.0515 (analyte) and m/z 559.0649 (internal standard), this assay demonstrated a linear relationship over a range of 1 fmol to 1 pmol of N7-HEG versus 20 fmol of [(13)C(4)]-N7-HEG on column. The limit of detection (LOD) for the complete assay was 600 amol (S/N = 5) injected on column. The variation of this assay was within 15% from 1 to 20 fmol of N7-HEG versus 2 fmol of [(13)C(4)]-N7-HEG with four replications for each calibration standard. Two hundred to three hundred micrograms of spleen DNA of control rats and mice and 100 microg of spleen DNA of rats and mice exposed to 3000 ppm ethylene for 6 h/day for 5 days were analyzed using GC/EC/NCI-HRMS. The amounts of N7-HEG varied from 0.2 to 0.3 pmol/micromol of guanine in tissues of control rats. Ethylene-exposed animals had 5-15-fold higher N7-HEG levels than controls. This assay was able to quantitate N7-HEG in 25-30 microg of DNA from human lymphocytes with excellent specificity. This was due in part to human tissues having 10-15-fold higher amounts of endogenous N7-HEG than rodents. These results show that this GC/EC/NCI-HRMS method is highly sensitive and specific and can be used in biological monitoring and molecular dosimetry and molecular epidemiology studies.     

电子轰击离子化气相质谱法测定人类血浆中的丙卡特罗(英文)

目的:建立一种简便灵敏的气相质谱法用于测定丙卡特罗的血药浓度。方法:采用电子轰击离子化气相质谱法,以丙咪嗪做内标,样品采用液-液萃取、衍生化处理,分离柱为毛细管柱,进样器和接口温度分别为280℃和250℃,载气(氦气)流速为0.8 mL·min~(-1),进样口选择脉冲不分流模式,离子源和四极杆的温度分别为230℃和150℃。结果:测定方法的检测限为5 ng·L~(-1);线性范围为10-10000 ng·L~(-1);日内(n=5)和日间(n=5)变异系数均小于10％,平均回收率为99.1％±1.3％。结论:本方法灵敏、简便,可用于丙卡特罗的药代动力学研究。     

The determination of 4,4'-methylenebis (2-chloroaniline) in urine by electron capture gas chromatography

The development and use of a gas chromatographic method for monitoring workers who are occupationally exposed to 4,4'-methylenebis(2-chloroaniline) (MBOCA) is reported. The increase in ether-extractable MBOCA on mild hydrolysis is determined. The analytical conditions for a specific and sensitive electron capture gas chromatographic method that will measure both "free" MBOCA and "total" MBOCA are established. It is suggested that workers should be monitored by the measurement of "total" urinary MBOCA.     

Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry

A previously reported procedure for quantification of LSD in urine was modified to permit measurement of the drug in plasma. After addition of deuterium-labelled LSD, the plasma is extracted and the extract is treated with trifluoroacetylimidazole to convert the LSD to its N-trifluoroacetyl derivative. The derivatized LSD is analyzed by capillary column gas chromatography/negative ion chemical ionization. Plasma fortified with known concentrations of LSD gave linear responses from 0.1 to 3.0 ng/mL with this assay. The method was used to determine pharmacokinetic parameters for LSD after oral administration (1 microgram/kg) to a male volunteer. The apparent plasma half-life was determined to be 5.1 h. The peak plasma concentration of 1.9 ng/mL occurred 3 h after administration.     

Determination of dextromoramide by capillary gas chromatography and electron impact mass spectrometry

A sensitive and specific quantitative assay for the determination of dextromoramide in human fluids and tissues is described. Dextromoramide and an internal standard, SKF 525 A, are isolated by a basic extraction and back-extraction process. The final extract is separated on a 25-m capillary column B.P. 1 and drugs are detected by selected ion monitoring at m/z 100 and m/z 86 for dextromoramide and the internal standard, respectively. The minimum detectable quantities are 0.5 and 0.3 ng/mL, for dextromoramide in plasma and urine, respectively. Coefficients of variation for within-run data were less than 6%.     

Determination of isoxsuprine in human plasma by gas chromatography with electron capture detection

A rapid and sensitive gas chromatographic method for the determination of the beta-adrenergic agent isoxsuprine in human plasma has been developed. The procedure involves the extraction of the drug with ether and an internal standard (propranolol) from plasma at alkaline pH, solvent evaporation, and the formation of a tri-trifluoroacetyl derivative by reaction with trifluoroacetic anhydride in ethyl acetate. Analyses were carried out by gas-liquid chromatography on a 3% OV-17 column using an electron capture detector. The minimum detectable amount of isoxsuprine was 0.5 ng/ml of plasma and the electron capture detector response was tested to be linear (r2 greater than 0.999) between 0.5 and 20 ng/ml. No interferences from endogenous substances were found. Precision of the method was found to be 9.9, and 6.1% coefficient of variation at 1 ng/ml and 10 ng/ml of plasma, respectively. Determination of isoxsuprine at the nanogram level in cord plasma samples from newborns at the time of the delivery was possible using the described procedure.     

Determination of guaifenesin in human serum by capillary gas chromatography and electron capture detection

A method for the quantitation of guaifenesin in human serum has been developed and validated. The procedure involves liquid-liquid extraction of the serum sample in the presence of mephenesin as an internal standard, followed by derivatization and analysis using capillary gas chromatography (GC) and electron capture detection (ECD). Different solvents were tested for extraction of guaifenesin from serum. n-Hexane/dichloromethane (1:1, v/v) gave the highest recovery and the lowest background and was chosen as the extraction solvent. After extraction, the residue of guaifenesin was derivatized at 60 degrees C for 30 min, with trifluoroacetic acid anhydride (TFAA) in toluene in the presence of pyridine. Excess trifluoroacetic acid anhydride was removed using dilute solution of ammonium hydroxide. The method proved to be linear over the range of 25.0-1000 ng/ml. Recovery of guaifenesin from spiked samples was consistent, averaging 75.5% at 50.0 ng/ml with a range of 72.0-80.0% (N = 8 determinations) and averaging 78% at 800 ng/ml with a range of 76.0-81.0% (N = 8 determinations). The internal standard recovery was also consistent averaging 72.8% with a range of 67.0-76.0% (N = 16 determinations).     

Analysis of tiadenol in human plasma by capillary gas chromatography with electron capture detection

A sensitive and specific method for the quantitative determination of tiadenol in human plasma is described. After addition of the internal standard, both compounds were quantitatively extracted into chloroform and then derivatized with heptafluorobutyric anhydride (the structures of both derivatives were confirmed by electron impact mass spectrometry). Quantitation was achieved by capillary gas chromatography, using a (63) Ni-electron capture detector. Linearity was observed in the concentration range 5-100 ng ml(-1) and the minimum concentration of tiadenol detectable in plasma was 2.0 ng ml(-1). The method was successfully applied to plasma specimens collected from healthy human volunteers following a single oral administration of 800 mg of tiadenol.     

Measurement of urinary N tau-methylhistamine excretion: correlation of a newly developed radioimmunoassay (RIA) with gas chromatography mass spectrometry (GCMS)

A newly developed radioimmunoassay (RIA, Y) for the determination of urinary N tau-methylhistamine concentrations was correlated with gas chromatography mass spectrometry (GCMS, X). In 34 urine samples, with histamine and N tau-methylhistamine levels within our reference values, the correlation was: Y = 1.47X -0.245 mumol/l (r = 0.92; p-slope less than or equal to 0.0001). In 14 pathological urine samples, derived from patients with mastocytosis and having upper reference values, the correlation was: Y = 1.75X - 1.02 mumol/l (r = 0.93; p-slope less than or equal to 0.001). In spite of the greater specificity of the monoclonal antibody for N tau-methylhistamine compared with that of histamine, relatively high urinary histamine concentrations gave a false positive influence on the RIA results, which was 100% when the histamine/N tau-methylhistamine ratio was about 19. Clear cases of mastocytosis can be diagnosed, using the RIA-kit, but for a more precise N tau-methylhistamine value GCMS analyses will remain necessary.     

Advanced glycation end products of DNA: quantification of N2-(1-Carboxyethyl)-2'-deoxyguanosine in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry

Methylglyoxal (MG) and related alpha-oxoaldehydes react with proteins, lipids, and DNA to give rise to covalent adducts known as advanced glycation end products (AGEs). Elevated levels of AGEs have been implicated in the pathological complications of diabetes, uremia, Alzheimer's disease, and possibly cancer. There is therefore widespread interest in developing sensitive methods for the in vivo measurement of AGEs as prognostic biomarkers and for treatment monitoring. The two diastereomeric MG-DNA adducts of N(2)-(1-carboxyethyl)-2'-deoxyguanosine (CEdG) are the primary glycation products formed in DNA; however, accurate assessment of their distribution in vivo has not been possible since there is no readily available quantitative method for CEdG determination in biological samples. To address these issues, we have developed a sensitive and quantitative liquid chromatography electrospray ionization tandem mass spectrometry assay using the stable isotope dilution method with an (15)N(5)-CEdG standard. Methods for CEdG determination in urine or tissue extracted DNA are described. Changes in urinary CEdG in diabetic rats in response to oral administration of the AGE inhibitor LR-90 are used to demonstrate the potential utility of the method for treatment monitoring. Both stereoisomeric CEdG adducts were detected in a human breast tumor and normal adjacent tissue at levels of 3-12 adducts/10(7) dG, suggesting that this lesion may be widely distributed in vivo. Strategies for dealing with artifactual adduct formation due to oxoaldehyde generation during DNA isolation and enzymatic workup procedures are described.     

Analysis of 3,N(4)-ethenocytosine in DNA and in human urine by isotope dilution gas chromatography/negative ion chemical ionization/mass spectrometry.

The promutagenic etheno DNA adducts have been detected in tissue DNA of rodents and humans from various exogenous and endogenous sources. While other etheno DNA adducts have been detected and quantified by isotope dilution gas chromatography/negative ion chemical ionization/mass spectrometry (GC/NICI/MS), similar analysis for 3,N(4)-ethenocytosine (epsilonCyt) has not been available. In this report, a GC/NICI/MS assay was developed for detection and quantification of epsilonCyt in DNA and in human urine samples. The stable isotope of epsilonCyt with 7 mass units higher than the normal epsilonCyt was synthesized and used as internal standard of the assay. The adduct-enriched fraction of DNA hydrolysate was derivatized with pentafluorobenzyl bromide before GC/NICI/MS analysis with selective ion monitoring at [M - 181](-) fragments of pentafluorobenzylated epsilonCyt and its isotope analogue. One femtogram (S/N > 40) of pentafluorobenzylated epsilonCyt was detected when injected on column with selective ion monitoring mode. The limit of quantification for the entire assay was 7.4 fmol of epsilonCyt, which was approximately one thousand times lower than that of the HPLC/fluorescence assay for the nucleoside 3,N(4)-etheno-2'-deoxycytidine in DNA. Analysis of chloroacetaldehyde-treated calf thymus DNA by both GC/NICI/MS and HPLC/fluorescence methods provided similar adduct levels and thus verified the assay. This GC/NICI/MS method was used for analysis of epsilonCyt in two smokers' urine samples and the average level of epsilonCyt was 101 +/- 17 pg/mL/g of creatinine. Thus, quantification of epsilonCyt in DNA and in urine by this highly specific and ultrasensitive isotope dilution GC/NICI/MS assay may facilitate research on the role of epsilonCyt in carcinogenesis and in cancer development.     

Determination of LSD in urine by capillary column gas chromatography and electron impact mass spectrometry

A procedure for the determination of LSD (lysergic acid diethylamide) in urine at concentrations as low as 0.5 ng/ml is presented. After addition of deuterium-labeled LSD as the internal standard, a rapid n-butyl chloride extraction of LSD from urine at pH 8 is followed by formation of the trimethylsilyl (TMS) derivative by treatment with N,O-bis(trimethylsilyl)trifluoroacetamide. The TMS derivative of LSD is identified and quantified by selected ion monitoring with a fused-silica capillary column and electron impact ionization. The procedure was used to monitor LSD concentrations in urine for eight hours following oral administration of 70.5 micrograms of LSD to two human volunteers. Concentrations of LSD determined by the assay are compared with concentrations determined by two other methods of analysis, a radioimmunoassay and a high-performance liquid chromatographic (HPLC) assay. Data concerning the stability of LSD in urine are also presented.     

气相色谱-电子捕获法测定人血中舍曲林及其代谢产物去甲舍曲林的浓度

目的 :建立一种测定人血浆中舍曲林及其代谢产物去甲舍曲林浓度的方法。方法 :在碱性条件下用乙醚 正己烷 (80∶2 0 ,V/V)一次萃取 ,并以 10 %的三氟醋酐在 5 0℃下进行衍生化处理。采用 5 %苯基石英毛细管柱 (30m× 0 .2 5mm ,0 .2 5 μm) ,柱温 2 37℃。高纯度N2 为载气 ,流速 0 .75mL·min-1,分流比 2 5∶1,柱前压 115kPa。进样口温度 2 6 0℃ ,63 Ni电子捕获检测器 ,检测器温度 30 0℃。结果 :舍曲林和去甲舍曲林的线性范围均为 1.0～ 10 0 μg·L-1,最低检测浓度 0 .5 μg·L-1,相对回收率分别为96 .8%～ 10 8.2 %和 94 .5 %～ 10 6 .7% ,日内和日间RSD <8.5 %。结论 :本法简便、准确、灵敏 ,重现性好 ,是一种有效的检测人血浆中舍曲林及去甲舍曲林浓度的方法     

Quantitation of 5-(hydroxymethyl)uracil in DNA by gas chromatography with mass spectral detection.

5-(Hydroxymethyl)uracil is a product of oxidative DNA damage. This hydroxylated base was quantified in DNA by GC-MS using either acid or enzymatic hydrolysis of the DNA and isotopically labeled internal standards. Both 5-(hydroxymethyl)uracil and thymine were quantified in each DNA sample and the results expressed as a ratio. This procedure controlled for possible errors in the quantitation of DNA prior to hydrolysis and derivatization. In addition, quantitation of thymine was important due to possible variations in DNA hydrolysis efficiency for each sample. The isotopically labeled internal standards controlled for compound instability through the procedure and for variations in derivatization efficiency. The conditions used for acid hydrolysis of the DNA resulted in considerable degradation of 5-(hydroxymethyl)uracil; however, since isotopically labeled 5-(hydroxymethyl)uracil was added prior to acid treatment, 5-(hydroxymethyl)uracil still could be quantified. The degradation of 5-(hydroxymethyl)uracil was avoided using enzymatic hydrolysis of the DNA. In DNA that had been treated with hydrogen peroxide and iron in the presence of EDTA, the observed level of 5-(hydroxymethyl)uracil using enzymatic hydrolysis was 1.6-fold higher than when using acid hydrolysis of the DNA. With analysis of 2 micrograms of DNA, the detection limit for 5-(hydroxymethyl)uracil was 3/10(5) thymines.     

Detection and quantification of 1,N(6)-ethenoadenine in human placental DNA by mass spectrometry

Exocyclic DNA adducts have been reported to derive from various exogenous as well as endogenous sources, such as lipid peroxidation. Among them, 1,N(6)-ethenoadenine (epsilonAde) has previously been detected in tissue DNA of untreated rodents and humans by an immunoaffinity/(32)P-postlabeling method. This study reports detection and quantification of the endogenous epsilonAde adduct in the same human placental DNA by three independent assays, namely, GC/MS, LC/MS, and HPLC/fluorescence. Using a recently reported gas chromatography/negative ion chemical ionization/mass spectrometry (GC/NICI/MS) method [Chen, H.-J. C., et al. (1998) Chem. Res. Toxicol. 11, 1474], the level of epsilonAde in human placental DNA from a commercial source was found to be 2.3 adducts per 10(6) Ade bases. To confirm these findings, a liquid chromatography/electrospray ionization tandem mass spectrometry (LC/ESI/MS/MS) method was developed for epsilondAdo. With this LC/MS assay, epsilondAdo was detected at the level of 2.5 adducts per 10(6) dAdo nucleosides in the same human placental DNA. The stable isotopes of epsilonAde and epsilondAdo were added as internal standards in both GC/MS and LC/ESI/MS/MS assays, respectively, and thus provided high specificity, reproducibility, and accurate quantification. The relatively high levels of epsilonAde in this human placental DNA detected by mass spectrometry were further verified by HPLC/fluorescence analysis. The GC/MS method was validated by the HPLC/fluorescence assay using calf thymus DNA treated with chloroacetaldehyde or by the LC/MS method with 2, 3-epoxy-4-hydroxynonanal-modified calf thymus DNA. The epsilonAde level in human placental DNA freshly isolated in the presence of an antioxidant was similar to that in DNA from the commercial source. Since epsilonAde is a potential mutagenic lesion, analysis of epsilonAde by the specific and sensitive GC/NICI/MS method may provide a useful biomarker in cancer risk assessment.     

Confirmation and quantitation of barbiturates in human urine by gas chromatography/mass spectrometry

A sensitive, reliable, rapid quantitative method was developed for the N,N'-dimethyl derivatives of the 5,5'-disubstituted barbiturates (NNDM-barbiturates) after liquid-liquid extraction of 0.5-mL urine volumes. Each barbiturate was identified by GC/MS through the retention time for the total ion current and selected ion monitoring of four ion currents for each analyte. Quantitation was achieved through the base peak ion ratios for each NNDM-barbiturate/tolylbarbiturate (IS) over the concentration range 20-250 ng/mL (0.4 to 5 ng injected into the GC/MS). The limit of detection for all the barbiturates (p less than 0.01) was 20 ng/mL (0.4 ng total). The extraction efficiency ranged from 75 to 84% for all the barbiturates. The coefficient of variation of the barbiturates for the within-day run was 2.5 to 4.8% and between days was 6.7 to 8.6%. The percentage abundances of the ion current ratios for each NNDM-barbiturate was determined and found to be fully stable over a one-week period. This method is currently in routine use in our laboratory for the GC/MS confirmation of presumably positive barbiturate urine samples.